Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
404-02-005 ISMRM Abstract

Altered GABA and Glx levels: MRI markers correlate with clinical disability in relapsing-remitting multiple sclerosis

Primary: Neuro - Multiple Sclerosis
Secondary: Neuro - Gray Matter
404-02-005 · Altered Metabolism Across Healthy Aging and Neurological Disorders · Tuesday, 12 May, 8:20 AM–10:10 AM · Ballroom East
Keywords: Multiple Sclerosis In vivo proton magnetic resonance spectroscopy Gamma-aminobutyric acid Glutamate Clinical disability
Accepted
Ying Shi 1, Zhongkai Zhou2, jianxiu lian3,4,5, Pengfei Liu1
1The First Affiliated Hospital of Harbin Medical University, Harbin, China
2Beijing YouAn Hospital, Capital Medical University, China
3Philips Healthcare, Guangzhou, China
4Clinical and Technical Support, Philips Healthcare (Beijing), Beijing, China
5Philips Healthcare (Beijing), Beijing, China
Presenting Author: Ying Shi

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Marcus R: What Is Multiple Sclerosis? JAMA 2022, 328(20):2078.
2. Lublin F, Reingold S, Cohen J, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014, 83(3):278-286.
3. Massimo F, Wolfgang B, Declan C, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2019, 18(2).
4. Rafael LG, Gloria de Lourdes Llamosa-García V, Diego MJ, et al. Mechanisms of neurobehavioral abnormalities in multiple sclerosis: Contributions from neural and immune components. Clin Neurophysiol Pract 2019, 4(0).
5. Akyuz E, Celik B, Aslan F, et al. Exploring the Role of Neurotransmitters in Multiple Sclerosis: An Expanded Review. ACS chemical neuroscience 2023, 14(4):527-553.
6. Mandolesi G, Gentile A, Musella A, et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nature reviews Neurology 2015, 11(12):711-724.
7. Robert Z, Dejan J, Sirin G, et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother 2016, 16(7).
8. Rossi S, Muzio L, De Chiara V, et al. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain, behavior, and immunity 2011, 25(5):947-956.
9. Hetty P, Robin A dG, Graeme F M, et al. Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T. J Magn Reson Imaging 2016, 45(1).
10. Bhattacharyya P, Phillips M, Stone L, et al. Sensorimotor cortex gamma-aminobutyric acid concentration correlates with impaired performance in patients with MS. AJNR American journal of neuroradiology 2013, 34(9):1733-1739.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/404-02-005